Gemigliptin, Dapagliflozin, Empagliflozin DDI Study

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2018
LG‐DPCL018 (gemigliptin,SGLT‐2i DDI study) is to evaluate the safety and immunogenicity of gemilgliptin & dapagliflozin and gemigliptin & empagliflozin.
Epistemonikos ID: 9d5f488ced9be28d2c3e6c9233276e8b671650aa
First added on: May 21, 2024